Compounds for oncology indications, including: 1-the prevention of A) chemotherapy-induced nausea and vomiting (CINV), B) post-operative nausea and vomiting (PONV), and C) chronic cough and 2-treatment for patients with non-small cell lung cancer (NSCLC) whose tumors express an Anaplastic Lymphoma Kinase (ALK) fusion protein
Start Trial Get Full Profile
There’s no risk. Start your trial today to see profiles of TESARO plus 4808 other startups.